Stay updated on Upadacitinib vs Placebo in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib vs Placebo in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Upadacitinib vs Placebo in Psoriatic Arthritis Clinical Trial page
- Check4 days agoChange DetectedExpands and clarifies the Phase 3 PsA trial design for upadacitinib (two periods, explicit dosing arms, long-term extension) and updates drug naming from ABT-494 to upadacitinib, while broadening data-sharing details.SummaryDifference7%
- Check11 days agoChange DetectedThe page has been updated to include a new research article on the safety profile of Upadacitinib, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference1%
- Check18 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous facility names and locations across various countries, as well as new MedlinePlus related topics. Notably, the previous version's references to certain locations and topics have been removed.SummaryDifference17%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to Upadacitinib vs Placebo in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib vs Placebo in Psoriatic Arthritis Clinical Trial page.